Vanda Pharmaceuticals (VNDA) Current Deferred Revenue (2009 - 2014)

Vanda Pharmaceuticals has disclosed Current Deferred Revenue across 6 years of filings, most recently posting $174000.0 for Q4 2014.

• Current Deferred Revenue for Q4 2014 came in at $174000.0, down 99.81% year-over-year; the trailing twelve-month figure through Dec 2014 was $174000.0 (down 99.81% YoY), and the FY2014 annual result was $174000.0, down 99.81% from the prior year.
• Current Deferred Revenue came in at $174000.0 for Q4 2014 at Vanda Pharmaceuticals, down from $241000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $170.6 million in Q4 2010 to a low of $174000.0 in Q4 2014.
• The 5-year median for Current Deferred Revenue is $100.4 million (2013), against an average of $89.8 million.
• Across the five-year window, Current Deferred Revenue jumped 387.4% in 2012 and slumped 99.81% in 2014, its largest moves.
• Vanda Pharmaceuticals' Current Deferred Revenue stood at $170.6 million in 2010, then dropped by 15.7% to $143.9 million in 2011, then retreated by 18.62% to $117.1 million in 2012, then slipped by 22.88% to $90.3 million in 2013, then plunged by 99.81% to $174000.0 in 2014.
• The last three Current Deferred Revenue figures came in at $174000.0 (Q4 2014), $241000.0 (Q3 2014), and $75.1 million (Q2 2014), per Business Quant data.